Company intelligence / Profile preview

Leaf Expression Systems

Norwich, Norfolk, United Kingdomleafexpressionsystems.com ↗

Ownership: Private
Development stage: Commercial

Overview

Demonstrated rapid production of recombinant proteins including viral antigens and human receptors using plant-based systems. Supported COVID‑19 research with reagents such as ACE2 receptor and coronavirus nucleocapsid proteins. No clinical-stage therapeutic programs; focus on enabling clients' R&D through contract manufacturing.

Therapeutic areas: OtherInfectious Diseases
Modalities: Recombinant proteinVaccineAntibody (including monoclonal antibody)Enzyme replacement therapyBiologic
Industry: Contract Manufacturing Organization

Partnerships

European Union’s Horizon2020 PharmaFactory project consortium partners for pandemic response tools

Beyond the preview

Go deeper on Leaf Expression Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leaf Expression Systems.

Explore the full profile